Vera Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Vera Therapeutics reported approximately 700 patient start forms received since Trutacna’s July 7th, 2026 accelerated approval; management said the figure is its best early-launch demand measure.
- Net product revenue from Trutacna was $10.3 million in the third quarter of 2026, its first partial quarter of commercial sales; approximately half was demand and half was inventory.
- Research and development expenses were $41.3 million, compared with $56.5 million in the same period in 2025, while selling, general and administrative expenses were $61.4 million, compared with $27.5 million.
- Net loss was $93.7 million, or $1.30 per share, compared with $80.3 million, or $1.26 per share, in the prior-year period.
- For the nine months ended September 30th, 2026, net cash used in operating activities was $305.9 million, compared with $171.1 million in the prior-year period.
- As of September 30th, 2026, Vera had $384 million in cash, cash equivalents, and marketable securities; after a $75 million debt-facility draw in late October, the pro forma balance was $459 million, with up to $350 million remaining available under the facility, subject to certain conditions.
- In ORIGIN-3, which randomized and dosed 428 adults with IgA nephropathy, Trutacna reduced the risk of the composite kidney disease progression endpoint by 76% compared with placebo through 104 weeks; the hazard ratio was 0.24.
- At 52 weeks, placebo-adjusted eGFR change from baseline was 5.6 mL per minute, with eGFR of -0.1 mL per minute with Trutacna versus -5.7 with placebo; through 104 weeks, the placebo-adjusted annualized eGFR slope was 5.0 mL per minute per year.
- At 104 weeks, the placebo-adjusted reduction in uPCR was 60%; at 52 weeks, the placebo-adjusted reduction in uPCR was 51% and the reduction in galactose-deficient IgA1 was 67%. Hematuria resolved in 97% of Trutacna-treated patients with hematuria at baseline at 104 weeks.
- In ORIGIN-3, overall adverse events occurred in 75% of patients on Trutacna versus 78% on placebo; serious adverse events occurred in 7% versus 15%, and adverse events leading to discontinuation occurred in 2% versus 10%. No opportunistic infections, clinically relevant hypogammaglobulinemia, or deaths in the Trutacna group were reported.
- Interim PIONEER results showed atacizumab reduced proteinuria by 52% from baseline at week 24 in broader IgA nephropathy populations. In the primary membranous nephropathy cohort, anti-PLA2R antibody reductions were detectable as early as week 4 and proteinuria declined over the first 12 weeks.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and welcome to the Vera Therapeutics business update and financial results webcast for the quarter ended September 30, 2026. At this time, all participants are in listen-only mode. A question-and-answer session will follow the prepared remarks. As a reminder, this webcast is being recorded. If you have any objections, please disconnect at this time. I would now like to turn the call over to Josh Qin, Vice President of Corporate Finance and Investor Relations at Vera.
Please go ahead. Thank you, operator, and thank you, everyone, for joining us.
Earlier today, we issued a press release announcing our business highlights and financial results for the quarter ended September 30, 2026. A copy of the press release is available in the investors and media section of our website at ir.veratx.com. Before we begin, I would like to remind everyone that we will be making various remarks about future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. The company cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated.
We encourage everyone to review the company's filings with the SEC, including, without limitation, the company's most recent Form 10-K and Form 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. In addition, today's discussion includes results from ongoing clinical trials of atacicept in investigational uses that have not been approved by the FDA or any other regulatory authority. The full prescribing information for TRUTAKNA, including important safety information, is available on our website. Furthermore, the content of this webcast contains time-sensitive information that is accurate only as of the date of the live broadcast, November 5, 2026. Vera undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this broadcast. This webcast is being recorded, and an archive will be available on our website for 30 days.
With that, I will turn the call over to Dr. Marshall Fordyce, Founder and Chief Executive Officer.
Marshall? Thank you, Josh, and welcome, everyone.
Joining me today are Robert Brenner, our Chief Medical Officer, Matt Skelton, our Chief Commercial Officer, and Sean Grant, our Chief Financial Officer. The third quarter marked a major turning point for Vera. Following accelerated approval from the FDA in July, we launched TRUTAKNA, the first therapy approved in the U.S. that targets both BAFF and APRIL to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Since the accelerated approval of TRUTAKNA on July 7, we have received approximately 700 Patient Start Forms to date. This early momentum exemplifies our longstanding confidence in TRUTAKNA's potential to become a foundational therapy for IgA nephropathy, and it represents an important first step in delivering on our commitment to people living with this disease.
We are sharing this figure today because we believe it is the best measure of demand at this early stage of launch. Moving forward, we expect net product revenue to become the primary indicator of progress in addition to quarterly Patient Start Forms. The ORIGIN 3 final efficacy results, presented at ASN Kidney Week in October, strengthens the clinical foundation for this next phase of growth. As Rob will discuss, in the ORIGIN 3 final efficacy analysis, TRUTAKNA held the rate of kidney function decline to a physiologic level and reduced the risk of kidney disease progression by 76% compared with placebo through 104 weeks. We are pleased with the overall product profile and believe that we have one of the most robust data packages in the B-cell modulator class. These findings build on the proteinuria reduction at 36 weeks that supported accelerated approval.
This week, we submitted a supplemental Biologics License Application to the FDA, seeking full approval of TRUTAKNA in adults with primary IgA nephropathy based on the ORIGIN 3 final efficacy analysis. In addition, following a meeting with the Committee for Medicinal Products for Human Use at the European Medicines Agency, we plan to submit a Marketing Authorisation Application in the first quarter of 2027 for standard marketing authorization. Importantly, this application will leverage the same results presented at Kidney Week. These are important regulatory milestones as we advance toward potential full FDA approval in mid-2027, with potential approvals in other regions to follow. Alongside the U.S. launch and our pursuit of full approval in the U.S. and other regions, we are advancing the ongoing development program to expand the opportunity for atacicept.
This includes the phase II PIONEER basket trial in broader IgA nephropathy populations and other antibody-mediated kidney diseases, including encouraging interim results presented at ASN, as well as the once-monthly dose range finding study. This integrated program reflects our ambition to build on our progress in adult IgA nephropathy and bring new treatment options to more patients over time. With the early launch progress and expanding clinical evidence, Vera is now viewed as a leading kidney disease company. We are entering this next phase with enthusiasm and a clear focus on execution, bringing TRUTAKNA to more eligible patients today while developing opportunities to improve care for more patients in the future. With that, I will turn the call over to Robert Brenner for a recap of ASN and an update on our development activities.
Rob? Thank you, Marshall. Having spent the past few years working to advance atacicept through clinical development and U.S. regulatory approval, it is deeply rewarding to now see TRUTAKNA reaching patients.
I want to recognize our colleagues across the organization for the strong start to the product launch and their commitment to helping patients access treatment. Vera is advancing the ongoing clinical development program with the objective to bring atacicept to more patients and broaden its potential across autoimmune kidney diseases. That work begins with pursuing full approval in adults with primary IgA nephropathy at risk for disease progression, supported by the ORIGIN 3 final efficacy results. Two weeks ago, Dr. Jonathan Barratt presented the ORIGIN 3 final efficacy analysis as a late-breaking oral presentation in the opening plenary session of ASN Kidney Week, with simultaneous publication in The New England Journal of Medicine.
ORIGIN 3 randomized and dosed 428 adults with IgA nephropathy, and the final efficacy analysis met all pre-specified endpoints. On the key secondary endpoint, the placebo-adjusted eGFR change from baseline at 52 weeks was 5.6 mL/min. eGFR was minus 0.1 mL/min with TRUTAKNA compared with minus 5.7 with placebo on top of background therapy. Through 104 weeks, the placebo-adjusted annualized eGFR slope was 5.0 mL/min per year, with minus 0.6 with TRUTAKNA versus minus 5.6 with placebo. The eGFR benefit observed with TRUTAKNA was preserved across all pre-specified subgroups. These data demonstrate that patients treated with TRUTAKNA lose kidney function at a physiologic rate of approximately minus one mL/min per year, while patients on placebo and background therapy continue to lose eGFR at a pathologic rate and a high probability of developing kidney failure during their lifetime.
TRUTAKNA also reduced the risk of the composite kidney disease progression endpoint by 76% compared with placebo through 104 weeks, with a hazard ratio of 0.24. Eleven patients on TRUTAKNA, or 5%, had a sustained decline in eGFR of 30% or more, compared with 38 patients, or 18%, on placebo. Zero patients on TRUTAKNA progressed to dialysis, kidney transplantation, or death, compared with seven patients on placebo. At 52 weeks, the placebo-adjusted reduction in UPCR was 51%, and in galactose-deficient IgA1 was 67%, and hematuria resolved in 81% of TRUTAKNA-treated patients who had hematuria at baseline. At 104 weeks, the placebo-adjusted reduction in UPCR was 60%, and hematuria resolved in 97% of TRUTAKNA-treated patients who had hematuria at baseline. In the ORIGIN 3 final efficacy analysis, TRUTAKNA was well tolerated, with a safety profile generally comparable to placebo.
Overall adverse events occurred in 75% of patients on TRUTAKNA versus 78% on placebo. Serious adverse events occurred in 7% of patients on TRUTAKNA versus 15% on placebo, and adverse events leading to discontinuation occurred in 2% versus 10%, respectively. The most common adverse events associated with TRUTAKNA and placebo respectively were infections, 51% versus 52%, and local administration reactions, 30% versus 8%. Infection rates were similar between the two arms. There were no opportunistic infections or clinically relevant hypogammaglobulinemia, and no deaths occurred in the TRUTAKNA group. In the final efficacy analysis, 93% of TRUTAKNA-treated patients remained on therapy, compared with 79% on placebo. These results form the basis of the recently submitted sBLA, seeking full approval of TRUTAKNA in adults with primary IgA nephropathy, which is anticipated in mid-2027.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
16 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
